Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients
Phase 2
Terminated
- Conditions
- Mild Cognitive Impairment
- Registration Number
- NCT00202540
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Brief Summary
The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- Memory complaint
- Acetylcholinesterase inhibitors stopped at least 3 months before selection
Exclusion Criteria
- Dementia
- Parkinson's disease
- Vascular disorder
- Depression
- Epilepsy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Episodic memory
- Secondary Outcome Measures
Name Time Method Other cognitive domains, activities of daily living, global impression of change, MRI, safety.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie S18986's effects on episodic memory in MCI patients?
How does S18986 compare to cholinesterase inhibitors in treating MCI-related memory decline?
Which biomarkers correlate with S18986 response in mild cognitive impairment trials?
What are the long-term safety profiles of S18986 in NCT00202540 Servier's Phase 2 MCI study?
Are there combination therapies with S18986 for MCI that enhance cognitive outcomes?
Trial Locations
- Locations (1)
Hôpital la Grave-Casselardit
🇫🇷Toulouse, France